Paratek Pharmaceuticals, Inc.

NasdaqGM:PRTK Stok Raporu

Piyasa değeri: US$127.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Paratek Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Şu anda Paratek Pharmaceuticals için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

73.2%

Kazanç büyüme oranı

72.86%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi14.5%
Gelir büyüme oranı13.8%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme07 Aug 2023

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Apr 17

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) shares have had a really impressive month, gaining 77% after a shaky...
Seeking Alpha • Aug 24

Paratek Pharmaceuticals: Patience Is Wearing Thin

Summary Today, we put Paratek Pharmaceuticals in the spotlight for the first time since the early fall of last year. Paratek is advancing its flagship product NUZYRA nicely, but shareholders have not been rewarded to this point in time even as the shares have strong analyst support. What lies ahead for Paratek? An investment analysis follows in the paragraphs below. If you must speak ill of another, do not speak it, write it in the sand near the water's edge. ― Napoleon Hill Today, we are circling back on Paratek Pharmaceuticals (PRTK) for the first time since we posted this piece on this small antibiotic concern back in October of last year. Even as the company has demonstrated solid revenue growth, shareholders have not been rewarded in this name over the past year and patience is starting to wear thin. We update our investment thesis around Paratek Pharmaceuticals via the analysis below. Seeking Alpha Company Overview Paratek Pharmaceuticals is a Boston based antibiotic concern. The company's primary asset is NUZYRA. This is a once-daily oral and intravenous broad-spectrum antibiotic approved for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. The stock sells for around $2.75 a share and sports an approximate market cap of just under $150 million. August Company Presentation The company has some earlier stage candidates in its pipeline. None of them of note to this analysis given they are early in development. The company is advancing NUZYRA in Phase 2 development for Non-Tuberculous Mycobacteria or NTM for which it has Orphan Drug and Fast Track designations from the FDA. August Company Presentation Second Quarter Results On August 3rd, the company posted second quarter numbers. Paratek posted a GAAP loss of 33 cents a share, just a tad above the consensus. Net revenue for the second quarter of 2022 was $29.6 million. This compares to $19.6 million in 2Q2021 when excluding the first procurement of NUZYRA under the BARDA contract of $37.9 million (more detail on that contract in the last section of this article). August Company Presentation The $29.6 million in sales for the quarter included $25.1 million of revenues from NUZYRA's core commercial business. This was up from $14.9 million from the same period a year ago. The company also booked $4 million in sales from the BARDA contract and $600,000 in royalty revenue from SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. August Company Presentation Analyst Commentary & Balance Sheet Only three analyst firms have chimed in around Paratek so far in 2022. On February 10th, WBB Securities upgraded the shares to a Strong Buy with a $11 price target as the analyst there believes 'Nuzyra is a critically important antibiotic that has anchored the franchise'. This month BTIG ($30 price target) and H.C. Wainwright ($20 price target) both maintained their Buy ratings on the stock. Just under 10% of the outstanding float is currently held short. Four insiders sold just over $300,000 worth of shares collectively in August. That has been the only insider activity in the equity so far in 2022. The company ended the first half of this year with nearly $70 million in cash and marketable securities on its balance sheet. Management stated within its second quarter earnings press release that: Based upon the company's current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4 million as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even. August Company Presentation Verdict The current analyst consensus has the company losing a bit over 80 cents a share in FY2022 as revenues rise in the mid teens to some $150 million. Projections from three analyst firms that have provided estimates for FY2023 are in wide range both for earnings (A 42 cent a share loss to profits of $1.37 a share) and revenues ($195 million to $315 million).
Seeking Alpha • Aug 03

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Paratek Pharmaceuticals press release (NASDAQ:PRTK): Q2 GAAP EPS of -$0.33 beats by $0.01. Revenue of $29.6M (-48.5% Y/Y) beats by $0.42M. Based upon the company’s current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4M as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even.
Seeking Alpha • Jan 03

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

2021 revenue estimate: $128-139 million; 2022 revenue estimate: $200 million. Revenue estimates for CABP and ABSSSI near $400 million by 2028; NTM could generate even higher sales well into the 2030s. $304 million BARDA contract (2019-2023) provides a pathway to profitability by 4Q2022. Deeply undervalued: enterprise value of $369 million is less than 2X 2022 sales.
Seeking Alpha • Oct 18

The Play On Paratek Pharmaceuticals

Today, we take a quick look back at antibiotic concern Paratek Pharmaceuticals. While I am very underweight the antibiotic space due to the terrible economics there, Paratek has some unique features that make the stock one I own. An analysis and how I am positioned in Paratek Pharmaceuticals follows in the paragraphs below.
Seeking Alpha • Aug 07

Peeking Back In On Paratek Pharmaceuticals

The stock of Paratek Pharmaceuticals has fallen since we last took an in-depth look at this antibiotic company in March. Most of this is due to weakness in the sector. The company continues to make solid progress, and its shares are far below analyst firm price targets. A full and independent investment analysis follows in the paragraphs below.
Analiz Makalesi • Mar 01

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) is possibly approaching a major achievement in its business, so we would...
Analiz Makalesi • Feb 01

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

A look at the shareholders of Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) can tell us which group is most powerful...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:PRTK - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20252212-9N/A2
12/31/2024218-1430N/A3
12/31/2023163-46-10N/A2
6/30/2023177-63-23-23N/A
3/31/2023167-66-36-36N/A
12/31/2022160-64-66-66N/A
9/30/2022117-89-66-66N/A
6/30/2022111-86-27-27N/A
3/31/2022139-59-46-46N/A
12/31/2021130-59-49-48N/A
9/30/2021114-52-53-52N/A
6/30/2021104-54-108-107N/A
3/31/202155-87-95-95N/A
12/31/202047-97-104-103N/A
9/30/202040-99-116-115N/A
6/30/202030-111-115-114N/A
3/31/202023-121-129-129N/A
12/31/201917-129-134-134N/A
9/30/201925-124-118-117N/A
6/30/201921-124-110-110N/A
3/31/201919-120-98-98N/A
12/31/201817-112-81-81N/A
9/30/20185-111-85-85N/A
6/30/20185-101-80-80N/A
3/31/201813-89-73-73N/A
12/31/201713-89-80-79N/A
9/30/20178-94-82-80N/A
6/30/20178-96-95-94N/A
3/31/20170-108N/A-101N/A
12/31/20160-112N/A-94N/A
9/30/2016N/A-106N/A-86N/A
6/30/2016N/A-106N/A-78N/A
3/31/2016N/A-91N/A-70N/A
12/31/2015N/A-71N/A-55N/A
9/30/20154-61N/A-49N/A
6/30/20154-42N/A-30N/A
3/31/20154-29N/A-18N/A
12/31/20144-20N/A-19N/A
9/30/20140-12N/A-9N/A
6/30/20141-11N/A-8N/A
3/31/20140-11N/A-8N/A
12/31/20130-11N/A-6N/A
9/30/20131-37N/A-9N/A
6/30/20131-41N/A-11N/A
3/31/20133-45N/A-10N/A
12/31/20123-50N/A-12N/A
9/30/20124-28N/A-12N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PRTK önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.2% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: PRTK önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: PRTK önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: PRTK şirketinin gelirinin (yıllık 13.8% ) US pazarından (yıllık 11.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: PRTK şirketinin gelirinin (yıllık 13.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PRTK 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2023/09/22 11:06
Gün Sonu Hisse Fiyatı2023/09/20 00:00
Kazançlar2023/06/30
Yıllık Kazançlar2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Paratek Pharmaceuticals, Inc. 11 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Michael UlzBaird
Jason Matthew GerberryBofA Global Research
Timothy ChiangBTIG